Related Experiment Video
Updated: Aug 17, 2026
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
Therapeutic attack of hypoxic cells of solid tumors: presidential address
1Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510.
Abstract:
Hypoxic cells of solid tumors are relatively resistant to therapeutic assault. Studies have demonstrated that oxygen-deficient tumor cells exist in an environment conducive to reductive reactions making hypoxic cells particularly sensitive to bioreductive alkylating agents. Mitomycin C, the prototype bioreductive alkylating agent available for clinical use, is capable of preferentially killing oxygen-deficient cells both in vitro and in vivo. This phenomenon is at least in part the result of differences in the uptake and metabolism of mitomycin C by hypoxic and oxygenated tumor cells, with the ultimate critical lesion being the cross-linking of DNA by the mitomycin antibiotic. The combination of mitomycin C with X-irradiation, to attack hypoxic and oxygenated tumor cell populations, respectively, has led to enhanced antitumor effects in mice bearing solid tumor implants and in patients with cancer of the head and neck. More efficacious kill of hypoxic tumor cells may be possible by the use of dicoumarol in combination with mitomycin or by the use of the related antibiotic porfiromycin. The findings support the use of an agent with specificity for hypoxic tumor cells in potentially curative regimens for solid tumors.
Insights
Hypoxic tumor cells, resistant to therapy, are sensitive to bioreductive agents like Mitomycin C. Combining Mitomycin C with X-irradiation enhances antitumor effects, offering potential for curative regimens.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Solid tumors contain hypoxic cells resistant to conventional therapies.
- Hypoxic tumor microenvironments favor reductive reactions, sensitizing cells to bioreductive agents.
- Mitomycin C is a clinically available bioreductive alkylating agent with preferential activity against oxygen-deficient cells.
Purpose of the Study:
- To investigate the efficacy of bioreductive agents, specifically Mitomycin C, against hypoxic tumor cells.
- To explore the combination of Mitomycin C with X-irradiation for enhanced antitumor effects.
- To evaluate novel strategies for targeting hypoxic tumor cell populations.
Main Methods:
- In vitro and in vivo studies assessing Mitomycin C uptake and metabolism in hypoxic versus oxygenated tumor cells.
- DNA cross-linking as the critical lesion induced by Mitomycin C.
- Combination therapy studies involving Mitomycin C and X-irradiation in mouse tumor models and head and neck cancer patients.
Main Results:
- Mitomycin C preferentially kills hypoxic tumor cells due to differential uptake and metabolism.
- Combination of Mitomycin C with X-irradiation demonstrated enhanced antitumor effects in preclinical and clinical settings.
- Dicoumarol or porfiromycin may offer more effective killing of hypoxic tumor cells.
Conclusions:
- Bioreductive alkylating agents like Mitomycin C show promise for targeting resistant hypoxic tumor cells.
- Combination strategies, including Mitomycin C with X-irradiation, can improve therapeutic outcomes.
- Targeting hypoxic tumor cells with specific agents is a viable approach for curative cancer treatment.
More Related Videos
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
09:12Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
Published on: June 14, 2024
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers